REVIEW

An overview of overactive bladder

I Putu Gde Fredy Gunawan , I Nyoman Suarjana, Kadek Frida Wulandari

I Putu Gde Fredy Gunawan
Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia. Email: putu.gde.fredy@gmail.com

I Nyoman Suarjana
Departement of Internal Medicine, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia

Kadek Frida Wulandari
Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
Online First: April 28, 2021 | Cite this Article
Gunawan, I., Suarjana, I., Wulandari, K. 2021. An overview of overactive bladder. Bali Medical Journal 10(1): 208-210. DOI:10.15562/bmj.v10i1.2266


Overactive bladder (OAB) is a common multifactorial disease that can cause a burden to the patient. Despite being a symptomatic diagnosis, several urological examinations need to be done to rule out other possible causes. The management of OAB is specific to each individual, from the very first line of behavioral therapy to surgical for an extremely rare case of OAB. This overview will look out for OAB thoroughly from the epidemiological burden, pathophysiology, clinical presentation and diagnosis, and the current treatment of OAB.

References

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. International Urogynecology Journal. 2009;21(1):5–26. Available from: http://dx.doi.org/10.1007/s00192-009-0976-9

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU International. 2011;108(7):1132–8. Available from: http://dx.doi.org/10.1111/j.1464-410x.2010.09993.x

Lapitan MC, Chyeon PLH. The Epidemiology of Overactive Bladder among Females in Asia: A Questionnaire Survey. International Urogynecology Journal and Pelvic Floor Dysfunction. 2001;12(4):226–31. Available from: http://dx.doi.org/10.1007/s001920170043

Moorthy P, Lapitan MC, Quek PLC, Lim PHC. Prevalence of overactive bladder in Asian men: an epidemiological survey. BJU International. 2004;93(4):528–31. Available from: http://dx.doi.org/10.1111/j.1464-410x.2003.04682.x

Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: A systematic literature review. Neurourology and Urodynamics. 2018;37(4):1241–9. Available from: http://dx.doi.org/10.1002/nau.23477

Bartley JM, Blum ES, Sirls LT, Peters KM. Understanding Clinic Options for Overactive Bladder. Current Urology Reports. 2013;14(6):541–8. Available from: http://dx.doi.org/10.1007/s11934-013-0353-6

Meng E, Lin W-Y, Lee W-C, Chuang Y-C. Pathophysiology of Overactive Bladder. LUTS: Lower Urinary Tract Symptoms. 2012;4:48–55. Available from: http://dx.doi.org/10.1111/j.1757-5672.2011.00122.x

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. Journal of Urology. 2012;188(6S):2455–63. Available from: http://dx.doi.org/10.1016/j.juro.2012.09.079

Robinson D, Cardozo L. Managing overactive bladder. Climacteric. 2019;22(3):250–6. Available from: http://dx.doi.org/10.1080/13697137.2018.1552254

Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10(10):CD005654–CD005654. Available from: https://pubmed.ncbi.nlm.nih.gov/30288727

White N, Iglesia CB. Overactive Bladder. Obstetrics and Gynecology Clinics of North America. 2016;43(1):59–68. Available from: http://dx.doi.org/10.1016/j.ogc.2015.10.002

Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology. 2018;73(4):596–609. Available from: http://dx.doi.org/10.1016/j.eururo.2017.12.031

Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol. 2018;10(12):411–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30574201

Gong Q-Q, Xu Y-Q, Xu J, Ding X-Y, Guo C. Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder. Front Pharmacol. 2020;10:1618–1618. Available from: https://pubmed.ncbi.nlm.nih.gov/32009968

Bhide AA, Tailor V, Fernando R, Khullar V, Digesu GA. Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy. Int Urogynecol J. 2019/12/18 ed. 2020;31(5):865–70. Available from: https://pubmed.ncbi.nlm.nih.gov/31853597

Tutolo M, Ammirati E, Van der Aa F. What Is New in Neuromodulation for Overactive Bladder? European Urology Focus. 2018;4(1):49–53. Available from: http://dx.doi.org/10.1016/j.euf.2018.04.019

Banakhar MA, Al-Shaiji T, Hassouna M. Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem. Ther Adv Urol. 2012;4(4):179–85. Available from: https://pubmed.ncbi.nlm.nih.gov/22852028

Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6‐months in subjects with mild symptoms of overactive bladder. Neurourology and Urodynamics. 2014;34(3):224–30. Available from: http://dx.doi.org/10.1002/nau.22544


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0